Please wait a minute...
 Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact us
Early Edition  //  Current Issue  //  Open Special Issues  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited
Aging and disease    2015, Vol. 6 Issue (2) : 131-148     DOI: 10.14336/AD.2014.0423
Review Article |
The Role of the Tripartite Glutamatergic Synapse in the Pathophysiology of Alzheimer’s Disease
Rudy Carolyn C.1, Hunsberger Holly C.1, Weitzner Daniel S.1, Reed Miranda N.1,2,3,*()
1Behavioral Neuroscience, Department of Psychology, West Virginia University, Morgantown, WV, 26506, USA
2Center for Neuroscience, West Virginia University, Morgantown, WV, 26506, USA
3Center for Basic and Translational Stroke Research, West Virginia University, Morgantown, WV, 26506, USA
Download: PDF(915 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks    

Alzheimer’s disease (AD) is the most common form of dementia in individuals over 65 years of age and is characterized by accumulation of beta-amyloid (Aβ) and tau. Both Aβ and tau alter synaptic plasticity, leading to synapse loss, neural network dysfunction, and eventually neuron loss. However, the exact mechanism by which these proteins cause neurodegeneration is still not clear. A growing body of evidence suggests perturbations in the glutamatergic tripartite synapse, comprised of a presynaptic terminal, a postsynaptic spine, and an astrocytic process, may underlie the pathogenic mechanisms of AD. Glutamate is the primary excitatory neurotransmitter in the brain and plays an important role in learning and memory, but alterations in glutamatergic signaling can lead to excitotoxicity. This review discusses the ways in which both beta-amyloid (Aβ) and tau act alone and in concert to perturb synaptic functioning of the tripartite synapse, including alterations in glutamate release, astrocytic uptake, and receptor signaling. Particular emphasis is given to the role of N-methyl-D-aspartate (NMDA) as a possible convergence point for Aβ and tau toxicity.

Keywords Beta-amyloid      tau      Alzheimer’s disease      excitotoxicity      glutamate      NMDA      astrocytes      tripartite synapse     
Corresponding Authors: Reed Miranda N.     E-mail:
About author:

present address: Kunming Biomed International, Kunming, Yunnan, 650500, China

Issue Date: 25 March 2015
E-mail this article
E-mail Alert
Articles by authors
Rudy Carolyn C.
Hunsberger Holly C.
Weitzner Daniel S.
Reed Miranda N.
Cite this article:   
Rudy Carolyn C.,Hunsberger Holly C.,Weitzner Daniel S., et al. The Role of the Tripartite Glutamatergic Synapse in the Pathophysiology of Alzheimer’s Disease[J]. Aging and disease, 2015, 6(2): 131-148.
URL:     OR
Figure 1.  The tripartite glutamate synapse. In the presynaptic neuron, glutamine (Gln) is converted to glutamate (Glu) by glutaminase and packaged into synaptic vesicles by the vesicular glutamate transporter (VGLUT). SNARE complex proteins mediate the fusion of vesicles with the presynaptic membrane. Astrocytes also release glutamate via the cystine-glutamate antiporter (Xc). Following release into the extracellular space, glutamate binds to presynaptic (mGluR2/3 and mGluR4/8), synaptic (S-NMDAR and AMPAR) and peri-/extra- synaptic (mGluR1/5 and E-NMDAR) glutamate receptors. Glutamate is cleared from the synaptic space through excitatory amino acid transporters (EAATs) on neighboring astrocytes (GLAST and GLT-1) and, to a lesser extent, on neurons (EAAT3). Glutamate is converted to glutamine by glutamine synthetase within the astrocyte before being transported to presynaptic neurons, thereby completing the glutamate-glutamine cycle.
mGluR GroupSubtypeGlutamate Receptor Affinity (EC50) [178]Location*Function*
Group ImGluR19Postsynaptic [179]Enhances excitability, synaptic plasticity, LTP/LTD [180, 181]
mGluR510Astrocytes [182]Elevates intracellular calcium [183, 184]
Group IImGluR24Presynaptic Inhibition of presynaptic glutamate [185]; LTD [186]
mGluR33Astrocytes [187]Inhibition of cystine/glutamate antiporter [26]
Group IIImGluR45Presynaptic [188] Inhibition of presynaptic glutamate [189]
mGluR71000Astrocytes [190]Increases glutamate uptake [187]
mGluR82.5 [191]
Table 1  Primary locations and functions of metabotropic glutamate receptors in the tripartite synapse.
Figure 2.  Aβ-mediated increases in extracellular glutamate and the resulting excitotoxicity. (1) Aβ increases presynaptic release of glutamate. (2) Aβ elevates astrocytic calcium via stimulation of astrocytic α7 nicotinic receptors, resulting in astrocytic glutamate release via an unknown mechanism. (3) Aβ decreases glutamate clearance from the synapse, thereby prolonging the duration of glutamate in the synapse and potentially resulting in the spread of glutamate to neighboring synapses. (4) Prolonged activation of S-NMDARs and AMPARs resulting from increased extracellular glutamate is predicted to cause desensitization and internalization of NMDA/AMPA, resulting in synaptic depression. (5) Glutamate spillover activates E-NMDARs, resulting in multiple deleterious downstream events, including an increase in tau kinase activity, cell death, and blockade of long-term potentiation (LTP) and CREB phosphorylation (pCREB).
Figure 3.  Tau-mediated excitotoxicity. (A) In healthy neurons, tau transports Fyn to the dendritic spine where Fyn, a tyrosine kinase that phosphorylates the NR2B receptor subunit Tyr1472, stabilizes the NR2B:PSD95 complex. (B) In the presence of Aβ and/or hyperphosphorylated tau (ptau), stabilization of the NR2B:PSD95 complex enhances glutamatergic excitotoxicity. (C) Removal of tau or Fyn prevents glutamatergic excitotoxicity mediated by Aβ.
[1] Alzheimer’s Association,Thies W,Bleiler L (2011). 2011 Alzheimer’s disease facts and figures. Alzheimer’s and Dementia, 7: 208–244
[2] Thies W,Bleiler L (2013). 2013 Alzheimer’s disease facts and figures. Alzheimer’s and Dementia, 9: 208–245
[3] Serrano-Pozo A,Frosch MP,Masliah E,Hyman BT (2011). Neuropathological alterations in Alzheimer disease. Cold Spring Harbor perspectives in medicine, 1: a006189
[4] Terry RD,Masliah E,Salmon DP,Butters N,DeTeresa R,Hill R, et al. (1991). Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Annals of neurology, 30: 572–580
[5] Mucke L,Masliah E,Yu GQ,Mallory M,Rockenstein EM,Tatsuno G, et al. (2000). High-level neuronal expression of abeta 1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. The Journal of neuroscience, 20: 4050–4058
[6] Hsia AY,Masliah E,McConlogue L,Yu GQ,Tatsuno G,Hu K, et al. (1999). Plaque-independent disruption of neural circuits in Alzheimer’s disease mouse models. Proceedings of the National Academy of Sciences of the United States of America, 96: 3228–3233
[7] Tackenberg C,Grinschgl S,Trutzel A,Santuccione AC,Frey MC,Konietzko U, et al. (2013). NMDA receptor subunit composition determines beta-amyloid-induced neurodegeneration and synaptic loss. Cell Death and Disease, 4: 1–10
[8] Curtis DR,Phillis JW,Watkins JC (1960). The chemical excitation of spinal neurones by certain acidic amino acids. The Journal of physiology, 150: 656–682
[9] Sheldon AL,Robinson MB (2007). The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochemistry international, 51: 333–355
[10] Bliss TV,Collingridge GL (1993). A synaptic model of memory: long-term potentiation in the hippocampus. Nature, 361: 31–39
[11] Bliss TV,Lomo T (1973). Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. The Journal of physiology, 232: 331–356
[12] Bliss TV,Gardner-Medwin AR (1973). Long-lasting potentiation of synaptic transmission in the dentate area of the unanaestetized rabbit following stimulation of the perforant path. The Journal of physiology, 232: 357–374
[13] Olney JW,Price MT,Samson L,Labruyere J (1986). The role of specific ions in glutamate neurotoxicity. Neuroscience letters, 65: 65–71
[14] Ittner LM,Ke YD,Delerue F,Bi M,Gladbach A,van Eersel J, et al. (2010). Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models. Cell, 142: 387–397
[15] Hardingham GE,Bading H (2010). Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci., 11: 682–696. Epub 2010 Sep 2015.
[16] Hardingham GE,Fukunaga Y,Bading H (2002). Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nature neuroscience, 5: 405–414
[17] Parpura V,Basarsky TA,Liu F,Jeftinija K,Jeftinija S,Haydon PG (1994). Glutamate-mediated astrocyte-neuron signalling. Nature, 369: 744–747
[18] Krebs HA,Johnson WA (1937). Metabolism of ketonic acids in animal tissues. Biochem J, 31: 645–660
[19] Norenberg MD,Martinez-Hernandez A (1979). Fine structural localization of glutamine synthetase in astrocytes of rat brain. Brain research, 161: 303–310
[20] Li D,Herault K,Silm K,Evrard A,Wojcik S,Oheim M, et al. (2013). Lack of evidence for vesicular glutamate transporter expression in mouse astrocytes. The Journal of neuroscience 33: 4434–4455
[21] Bollmann JH,Sakmann B,Borst JG (2000). Calcium sensitivity of glutamate release in a calyx-type terminal. Science (New York, N.Y.), 289: 953–957
[22] Sudhof TC (2004). The synaptic vesicle cycle. Annu Rev Neurosci, 27: 509–547
[23] Takamori S,Rhee JS,Rosenmund C,Jahn R (2000). Identification of a vesicular glutamate transporter that defines a glutamatergic phenotype in neurons. Nature, 407: 189–194
[24] Montana V,Ni Y,Sunjara V,Hua X,Parpura V (2004). Vesicular glutamate transporter-dependent glutamate release from astrocytes. The Journal of neuroscience, 24: 2633–2642
[25] Bannai S (1986). Exchange of cystine and glutamate across plasma membrane of human fibroblasts. The Journal of biological chemistry, 261: 2256–2263
[26] Baker DA,Xi ZX,Shen H,Swanson CJ,Kalivas PW (2002). The origin and neuronal function of in vivo nonsynaptic glutamate. The Journal of neuroscience, 22: 9134–9141
[27] Hollmann M,O’Shea-Greenfield A,Rogers SW,Heinemann S (1989). Cloning by functional expression of a member of the glutamate receptor family. Nature, 342: 643–648
[28] Sugiyama H,Ito I,Hirono C (1987). A new type of glutamate receptor linked to inositol phospholipid metabolism. Nature, 325: 531–533
[29] Nakanishi S (1992). Molecular diversity of glutamate receptors and implications for brain function. Science (New York, N.Y.), 258: 597–603
[30] Traynelis SF,Wollmuth LP,McBain CJ,Menniti FS,Vance KM,Ogden KK, et al. (2010). Glutamate receptor ion channels: structure, regulation, and function. Pharmacological reviews, 62: 405–496
[31] Curtis DR,Watkins JC (1963). Acidic amino acids with strong excitatory actions on mammalian neurones. The Journal of physiology, 166: 1–14
[32] Safferling M,Tichelaar W,Kummerle G,Jouppila A,Kuusinen A,Keinanen K, et al. (2001). First images of a glutamate receptor ion channel: oligomeric state and molecular dimensions of GluRB homomers. Biochemistry, 40: 13948–13953
[33] Tichelaar W,Safferling M,Keinanen K,Stark H,Madden DR (2004). The Three-dimensional Structure of an Ionotropic Glutamate Receptor Reveals a Dimer-of-dimers Assembly. Journal of molecular biology, 344: 435–442
[34] Nakagawa T,Cheng Y,Ramm E,Sheng M,Walz T (2005). Structure and different conformational states of native AMPA receptor complexes. Nature, 433: 545–549
[35] Sobolevsky AI,Rosconi MP,Gouaux E (2009). X-ray structure, symmetry and mechanism of an AMPA-subtype glutamate receptor. Nature, 462: 745–756
[36] Laube B,Kuhse J,Betz H (1998). Evidence for a tetrameric structure of recombinant NMDA receptors. The Journal of neuroscience, 18: 2954–2961
[37] Tang CM,Dichter M,Morad M (1989). Quisqualate activates a rapidly inactivating high conductance ionic channel in hippocampal neurons. Science (New York, N.Y.), 243: 1474–1477
[38] Chittajallu R,Vignes M,Dev KK,Barnes JM,Collingridge GL,Henley JM (1996). Regulation of glutamate release by presynaptic kainate receptors in the hippocampus. Nature, 379: 78–81
[39] Mayer ML,Westbrook GL,Guthrie PB (1984). Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones. Nature, 309: 261–263
[40] Lester RA,Clements JD,Westbrook GL,Jahr CE (1990). Channel kinetics determine the time course of NMDA receptor-mediated synaptic currents. Nature, 346: 565–567
[41] Laube B,Hirai H,Sturgess M,Betz H,Kuhse J (1997). Molecular determinants of agonist discrimination by NMDA receptor subunits: analysis of the glutamate binding site on the NR2B subunit. Neuron, 18: 493–503
[42] Panatier A,Theodosis DT,Mothet JP,Touquet B,Pollegioni L,Poulain DA, et al. (2006). Glia-derived D-serine controls NMDA receptor activity and synaptic memory. Cell, 125: 775–784
[43] Kleckner NW,Dingledine R (1988). Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science (New York, N.Y.), 241: 835–837
[44] Henneberger C,Papouin T,Oliet SH,Rusakov DA (2010). Long-term potentiation depends on release of D-serine from astrocytes. Nature, 463: 232–236
[45] Jahr CE,Stevens CF (1993). Calcium permeability of the N-methyl-D-aspartate receptor channel in hippocampal neurons in culture. Proceedings of the National Academy of Sciences of the United States of America, 90: 11573–11577
[46] Dingledine R (1983). N-methyl aspartate activates voltage-dependent calcium conductance in rat hippocampal pyramidal cells. The Journal of physiology, 343: 385–405
[47] MacDermott AB,Mayer ML,Westbrook GL,Smith SJ,Barker JL (1986). NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurones. Nature, 321: 519–522
[48] Choi DW (1987). Ionic dependence of glutamate neurotoxicity. The Journal of neuroscience, 7: 369–379
[49] Choi DW,Koh JY,Peters S (1988). Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists. The Journal of neuroscience: the official journal of the Society for Neuroscience, 8: 185–196
[50] Choi DW,Maulucci-Gedde M,Kriegstein AR (1987). Glutamate neurotoxicity in cortical cell culture. The Journal of neuroscience: the official journal of the Society for Neuroscience, 7: 357–368
[51] Kunishima N,Shimada Y,Tsuji Y,Sato T,Yamamoto M,Kumasaka T, et al. (2000). Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature, 407: 971–977
[52] Houamed KM,Kuijper JL,Gilbert TL,Haldeman BA,O’Hara PJ,Mulvihill ER, et al. (1991). Cloning, expression, and gene structure of a G protein-coupled glutamate receptor from rat brain. Science (New York, N.Y.), 252: 1318–1321
[53] Masu M,Tanabe Y,Tsuchida K,Shigemoto R,Nakanishi S (1991). Sequence and expression of a metabotropic glutamate receptor. Nature, 349: 760–765
[54] Nicoletti F,Wroblewski JT,Fadda E,Costa E (1988). Pertussis toxin inhibits signal transduction at a specific metabolotropic glutamate receptor in primary cultures of cerebellar granule cells. Neuropharmacology, 27: 551–556
[55] Nicoletti F,Meek JL,Iadarola MJ,Chuang DM,Roth BL,Costa E (1986). Coupling of inositol phospholipid metabolism with excitatory amino acid recognition sites in rat hippocampus. Journal of neurochemistry, 46: 40–46
[56] Abe T,Sugihara H,Nawa H,Shigemoto R,Mizuno N,Nakanishi S (1992). Molecular characterization of a novel metabotropic glutamate receptor mGluR5 coupled to inositol phosphate/Ca2+ signal transduction. The Journal of biological chemistry, 267: 13361–13368
[57] Nakajima Y,Iwakabe H,Akazawa C,Nawa H,Shigemoto R,Mizuno N, et al. (1993). Molecular characterization of a novel retinal metabotropic glutamate receptor mGluR6 with a high agonist selectivity for L-2-amino-4-phosphonobutyrate. The Journal of biological chemistry, 268: 11868–11873
[58] Okamoto N,Hori S,Akazawa C,Hayashi Y,Shigemoto R,Mizuno N, et al. (1994). Molecular characterization of a new metabotropic glutamate receptor mGluR7 coupled to inhibitory cyclic AMP signal transduction. The Journal of biological chemistry, 269: 1231–1236
[59] Tanabe Y,Masu M,Ishii T,Shigemoto R,Nakanishi S (1992). A family of metabotropic glutamate receptors. Neuron, 8: 169–179
[60] Tanabe Y,Nomura A,Masu M,Shigemoto R,Mizuno N,Nakanishi S (1993). Signal transduction, pharmacological properties, and expression patterns of two rat metabotropic glutamate receptors, mGluR3 and mGluR4. The Journal of neuroscience, 13: 1372–1378
[61] Palop JJ,Chin J,Mucke L (2006). A network dysfunction perspective on neurodegenerative diseases. Nature, 443: 768–773
[62] Danbolt NC (2001). Glutamate uptake. Prog Neurobiol, 65: 1–105
[63] Lehre KP,Levy LM,Ottersen OP,Storm-Mathisen J,Danbolt NC (1995). Differential expression of two glial glutamate transporters in the rat brain: quantitative and immunocytochemical observations. The Journal of neuroscience, 15: 1835–1853
[64] Lehre KP,Davanger S,Danbolt NC (1997). Localization of the glutamate transporter protein GLAST in rat retina. Brain research, 744: 129–137
[65] Crino PB,Jin H,Shumate MD,Robinson MB,Coulter DA,Brooks-Kayal AR (2002). Increased expression of the neuronal glutamate transporter (EAAT3/EAAC1) in hippocampal and neocortical epilepsy. Epilepsia, 43: 211–218
[66] Kanai Y,Hediger MA (1992). Primary structure and functional characterization of a high-affinity glutamate transporter. Nature, 360: 467–471
[67] Haugeto O,Ullensvang K,Levy LM,Chaudhry FA,Honore T,Nielsen M, et al. (1996). Brain glutamate transporter proteins form homomultimers. The Journal of biological chemistry, 271: 27715–27722
[68] Arriza JL,Eliasof S,Kavanaugh MP,Amara SG (1997). Excitatory amino acid transporter 5, a retinal glutamate transporter coupled to a chloride conductance. Proceedings of the National Academy of Sciences of the United States of America, 94: 4155–4160
[69] Nilsson A,Duan J,Mo-Boquist LL,Benedikz E,Sundstrom E (2007). Characterisation of the human NMDA receptor subunit NR3A glycine binding site. Neuropharmacology, 52: 1151–1159
[70] Kutsuwada T,Kashiwabuchi N,Mori H,Sakimura K,Kushiya E,Araki K, et al. (1992). Molecular diversity of the NMDA receptor channel. Nature, 358: 36–41
[71] Al-Hallaq RA,Jarabek BR,Fu Z,Vicini S,Wolfe BB,Yasuda RP (2002). Association of NR3A with the N-methyl-D-aspartate receptor NR1 and NR2 subunits. Molecular pharmacology, 62: 1119–1127
[72] Fukaya M,Hayashi Y,Watanabe M (2005). NR2 to NR3B subunit switchover of NMDA receptors in early postnatal motoneurons. The European journal of neuroscience, 21: 1432–1436
[73] Cao X,Cui Z,Feng R,Tang YP,Qin Z,Mei B, et al. (2007). Maintenance of superior learning and memory function in NR2B transgenic mice during ageing. The European journal of neuroscience, 25: 1815–1822
[74] von Engelhardt J,Coserea I,Pawlak V,Fuchs EC,Kohr G,Seeburg PH, et al. (2007). Excitotoxicity in vitro by NR2A- and NR2B-containing NMDA receptors. Neuropharmacology, 53: 10–17
[75] Braak H,Braak E (1998). Argyrophilic grain disease: frequency of occurrence in different age categories and neuropathological diagnostic criteria. Journal of neural transmission, 105: 801–819
[76] Du AT,Schuff N,Kramer JH,Ganzer S,Zhu XP,Jagust WJ, et al. (2004). Higher atrophy rate of entorhinal cortex than hippocampus in AD. Neurology, 62: 422–427
[77] van de Pol LA,van der Flier WM,Korf ES,Fox NC,Barkhof F,Scheltens P (2007). Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment. Neurology, 69: 1491–1497
[78] Groc L,Bard L,Choquet D (2009). Surface trafficking of N-methyl-d-aspartate receptors: Physiological and pathological perspectives. Neuroscience, 158: 4–18
[79] Newpher TM,Ehlers MD (2009). Spine microdomains for postsynaptic signaling and plasticity. Trends Cell Biol., 19: 218–227. Epub 2009 Mar 2028.
[80] Petralia RS,Sans N,Wang YX,Wenthold RJ (2005). Ontogeny of postsynaptic density proteins at glutamatergic synapses. Mol Cell Neurosci., 29: 436–452.
[81] Groc L,Choquet D (2006). AMPA and NMDA glutamate receptor trafficking: multiple roads for reaching and leaving the synapse. Cell Tissue Res., 326: 423–438
[82] Petralia RS,Wang YX,Hua F,Yi Z,Zhou A,Ge L, et al. (2010). Organization of NMDA receptors at extrasynaptic locations. Neuroscience, 167: 68–87.
[83] Liu Y,Wong TP,Aarts M,Rooyakkers A,Liu L,Lai TW, et al. (2007). NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J Neurosci, 27: 2846–2857.
[84] Mothet J-P,Parent AT,Wolosker H,Brady RO,Linden DJ,Ferris CD, et al. (2000). d-Serine is an endogenous ligand for the glycine site of the N-methyl-d-aspartate receptor. Proceedings of the National Academy of Sciences, 97: 4926–4931
[85] Papouin T,Ladepeche L,Ruel J,Sacchi S,Labasque M,Hanini M, et al. (2012). Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell, 150: 633–646
[86] Matsui T,Sekiguchi M,Hashimoto A,Tomita U,Nishikawa T,Wada K (1995). Functional comparison of D-serine and glycine in rodents: the effect on cloned NMDA receptors and the extracellular concentration. Journal of neurochemistry, 65: 454–458
[87] Henneberger C,Bard L,King C,Jennings A,Rusakov DA (2013). NMDA receptor activation: two targets for two co-agonists. Neurochemical research, 38: 1156–1162
[88] Gray John A, Nicoll Roger A Thinking Outside the Synapse: Glycine at Extrasynaptic NMDA Receptors. Cell, 150: 455–456
[89] Brightwell JJ,Gallagher M,Colombo PJ (2004). Hippocampal CREB1 but not CREB2 is decreased in aged rats with spatial memory impairments. Neurobiol Learn Mem, 81: 19–26
[90] Deisseroth K,Bito H,Tsien RW (1996). Signaling from synapse to nucleus: postsynaptic CREB phosphorylation during multiple forms of hippocampal synaptic plasticity. Neuron, 16: 89–101.
[91] Impey S,Smith DM,Obrietan K,Donahue R,Wade C,Storm DR (1998). Stimulation of cAMP response element (CRE)-mediated transcription during contextual learning. Nat Neurosci, 1: 595–601.
[92] Papadia S,Soriano FX,Leveille F,Martel MA,Dakin KA,Hansen HH, et al. (2008). Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nat Neurosci, 11: 476–487
[93] Acheson A,Conover JC,Fandl JP,DeChiara TM,Russell M,Thadani A, et al. (1995). A BDNF autocrine loop in adult sensory neurons prevents cell death. Nature, 374: 450–453
[94] Al-Mubarak B,Soriano FX,Hardingham GE (2009). Synaptic NMDAR activity suppresses FOXO1 expression via a cis-acting FOXO binding site: FOXO1 is a FOXO target gene. Channels (Austin, Tex.), 3: 233–238
[95] Mulholland PJ,Luong NT,Woodward JJ,Chandler LJ (2008). Brain-derived neurotrophic factor activation of extracellular signal-regulated kinase is autonomous from the dominant extrasynaptic NMDA receptor extracellular signal-regulated kinase shutoff pathway. Neuroscience, 151: 419–427
[96] Schafe GE,Atkins CM,Swank MW,Bauer EP,Sweatt JD,LeDoux JE (2000). Activation of ERK/MAP kinase in the amygdala is required for memory consolidation of pavlovian fear conditioning. The Journal of neuroscience, 20: 8177–8187
[97] Dick O,Bading H (2010). Synaptic activity and nuclear calcium signaling protect hippocampal neurons from death signal-associated nuclear translocation of FoxO3a induced by extrasynaptic N-methyl-D-aspartate receptors. The Journal of biological chemistry, 285: 19354–19361
[98] Xu J,Kurup P,Zhang Y,Goebel-Goody SM,Wu PH,Hawasli AH, et al. (2009). Extrasynaptic NMDA receptors couple preferentially to excitotoxicity via calpain-mediated cleavage of STEP. The Journal of neuroscience, 29: 9330–9343
[99] Qi X,Tang J,Pramanik R,Schultz RM,Shirasawa S,Sasazuki T, et al. (2004). p38 MAPK activation selectively induces cell death in K-ras-mutated human colon cancer cells through regulation of vitamin D receptor. The Journal of biological chemistry, 279: 22138–22144
[100] Dunah AW,Sirianni AC,Fienberg AA,Bastia E,Schwarzschild MA,Standaert DG (2004). Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32. Molecular pharmacology, 65: 121–129
[101] Hallett PJ,Spoelgen R,Hyman BT,Standaert DG,Dunah AW (2006). Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking. The Journal of neuroscience, 26: 4690–4700
[102] Snyder EM,Nong Y,Almeida CG,Paul S,Moran T,Choi EY, et al. (2005). Regulation of NMDA receptor trafficking by amyloid-beta. Nature neuroscience, 8: 1051–1058
[103] Allyson J,Dontigny E,Auberson Y,Cyr M,Massicotte G (2010). Blockade of NR2A-containing NMDA receptors induces Tau phosphorylation in rat hippocampal slices. Neural Plast., 2010: 340168. Epub 342010 May 340120.
[104] Amadoro G,Ciotti MT,Costanzi M,Cestari V,Calissano P,Canu N (2006). NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation. Proceedings of the National Academy of Sciences of the United States of America, 103: 2892–2897
[105] Xia P,Chen HS,Zhang D,Lipton SA (2010). Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J Neurosci, 30: 11246–11250.
[106] Song MS,Rauw G,Baker GB,Kar S (2008). Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation. The European journal of neuroscience, 28: 1989–2002
[107] Okamoto S,Pouladi MA,Talantova M,Yao D,Xia P,Ehrnhoefer DE, et al. (2009). Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med., 15: 1407–1413. Epub 2009 Nov 1415.
[108] Parsons CG,Stoffler A,Danysz W (2007). Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology, 53: 699–723
[109] Masters CL,Beyreuther K (1987). Neuronal origin of cerebral amyloidogenic proteins: their role in Alzheimer’s disease and unconventional virus diseases of the nervous system. Ciba Foundation symposium, 126: 49–64
[110] Kang J,Lemaire HG,Unterbeck A,Salbaum JM,Masters CL,Grzeschik KH, et al. (1987). The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature, 325: 733–736
[111] Glenner GG,Murphy MA (1989). Amyloidosis of the nervous system. Journal of the neurological sciences, 94: 1–28
[112] Palmert MR,Podlisny MB,Witker DS,Oltersdorf T,Younkin LH,Selkoe DJ, et al. (1989). The beta-amyloid protein precursor of Alzheimer disease has soluble derivatives found in human brain and cerebrospinal fluid. Proceedings of the National Academy of Sciences of the United States of America, 86: 6338–6342
[113] Joachim CL,Selkoe DJ (1992). The seminal role of beta-amyloid in the pathogenesis of Alzheimer disease. Alzheimer disease and associated disorders, 6: 7–34
[114] Hardy J,Allsop D (1991). Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci, 12: 383–388
[115] Barghorn S,Nimmrich V,Striebinger A,Krantz C,Keller P,Janson B, et al. (2005). Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer’s disease. Journal of neurochemistry, 95: 834–847
[116] Gong Y,Chang L,Viola KL,Lacor PN,Lambert MP,Finch CE, et al. (2003). Alzheimer’s disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proceedings of the National Academy of Sciences of the United States of America, 100: 10417–10422
[117] Lacor PN,Buniel MC,Furlow PW,Clemente AS,Velasco PT,Wood M, et al. (2007). Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer’s disease. J Neurosci, 27: 796–807
[118] Demuro A,Mina E,Kayed R,Milton SC,Parker I,Glabe CG (2005). Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. The Journal of biological chemistry, 280: 17294–17300
[119] Roselli F,Tirard M,Lu J,Hutzler P,Lamberti P,Livrea P, et al. (2005). Soluble beta-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. The Journal of neuroscience, 25: 11061–11070
[120] Christensen DZ,Kraus SL,Flohr A,Cotel MC,Wirths O,Bayer TA (2008). Transient intraneuronal A beta rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice. Acta neuropathologica, 116: 647–655
[121] Walsh DM,Klyubin I,Fadeeva JV,Cullen WK,Anwyl R,Wolfe MS, et al. (2002). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature, 416: 535–539
[122] Kamenetz F,Tomita T,Hsieh H,Seabrook G,Borchelt D,Iwatsubo T, et al. (2003). APP processing and synaptic function. Neuron, 37: 925–937
[123] Shankar GM,Bloodgood BL,Townsend M,Walsh DM,Selkoe DJ,Sabatini BL (2007). Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. The Journal of neuroscience, 27: 2866–2875
[124] Li S,Hong S,Shepardson NE,Walsh DM,Shankar GM,Selkoe D (2009). Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron, 62: 788–801
[125] Arias C,Arrieta I,Tapia R (1995). beta-Amyloid peptide fragment 25–35 potentiates the calcium-dependent release of excitatory amino acids from depolarized hippocampal slices. Journal of neuroscience research, 41: 561–566
[126] Brito-Moreira J,Paula-Lima AC,Bomfim TR,Oliveira FB,Sepulveda FJ,De Mello FG, et al. (2011). Abeta oligomers induce glutamate release from hippocampal neurons. Current Alzheimer research, 8: 552–562
[127] Pirttimaki TM,Codadu NK,Awni A,Pratik P,Nagel DA,Hill EJ, et al. (2013). alpha7 Nicotinic receptor-mediated astrocytic gliotransmitter release: Abeta effects in a preclinical Alzheimer’s mouse model. PloS one, 8: e81828
[128] Talantova M,Sanz-Blasco S,Zhang X,Xia P,Akhtar MW,Okamoto S, et al. (2013). Abeta induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proceedings of the National Academy of Sciences of the United States of America, 110: E2518–2527
[129] Noda M,Nakanishi H,Akaike N (1999). Glutamate release from microglia via glutamate transporter is enhanced by amyloid-beta peptide. Neuroscience, 92: 1465–1474
[130] Rush T,Buisson A (2014). Reciprocal disruption of neuronal signaling and Abeta production mediated by extrasynaptic NMDA receptors: a downward spiral. Cell and tissue research
[131] Parpura-Gill A,Beitz D,Uemura E (1997). The inhibitory effects of beta-amyloid on glutamate and glucose uptakes by cultured astrocytes. Brain research, 754: 65–71
[132] Matos M,Augusto E,Oliveira CR,Agostinho P (2008). Amyloid-beta peptide decreases glutamate uptake in cultured astrocytes: involvement of oxidative stress and mitogen-activated protein kinase cascades. Neuroscience, 156: 898–910
[133] Scimemi A,Meabon JS,Woltjer RL,Sullivan JM,Diamond JS,Cook DG (2013). Amyloid-beta1-42 slows clearance of synaptically released glutamate by mislocalizing astrocytic GLT-1. The Journal of neuroscience, 33: 5312–5318
[134] Harris ME,Wang Y,Pedigo NWJr.,Hensley K,Butterfield DA,Carney JM (1996). Amyloid beta peptide (25–35) inhibits Na+-dependent glutamate uptake in rat hippocampal astrocyte cultures. Journal of neurochemistry, 67: 277–286
[135] Bicca MA,Figueiredo CP,Piermartiri TC,Meotti FC,Bouzon ZL,Tasca CI, et al. (2011). The selective and competitive N-methyl-D-aspartate receptor antagonist,(-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid, prevents synaptic toxicity induced by amyloid-beta in mice. Neuroscience, 192: 631–641
[136] Mookherjee P,Green PS,Watson GS,Marques MA,Tanaka K,Meeker KD, et al. (2011). GLT-1 loss accelerates cognitive deficit onset in an Alzheimer’s disease animal model. Journal of Alzheimer’s disease, 26: 447–455
[137] Woltjer RL,Duerson K,Fullmer JM,Mookherjee P,Ryan AM,Montine TJ, et al. (2010). Aberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in Alzheimer disease. Journal of neuropathology and experimental neurology, 69: 667–676
[138] Pihlaja R,Koistinaho J,Malm T,Sikkila H,Vainio S,Koistinaho M (2008). Transplanted astrocytes internalize deposited beta-amyloid peptides in a transgenic mouse model of Alzheimer’s disease. Glia, 56: 154–163
[139] Wyss-Coray T,Loike JD,Brionne TC,Lu E,Anankov R,Yan F, et al. (2003). Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nature medicine, 9: 453–457
[140] Yamamoto N,Arima H,Naruse K,Kasahara R,Taniura H,Hirate H, et al. (2013). Ketamine reduces amyloid β-protein degradation by suppressing neprilysin expression in primary cultured astrocytes. Neuroscience letters, 545: 54–58
[141] Apelt J,Ach K,Schliebs R (2003). Aging-related down-regulation of neprilysin, a putative β-amyloid-degrading enzyme, in transgenic Tg2576 Alzheimer-like mouse brain is accompanied by an astroglial upregulation in the vicinity of β-amyloid plaques. Neuroscience letters, 339: 183–186
[142] Shelat PB,Chalimoniuk M,Wang JH,Strosznajder JB,Lee JC,Sun AY, et al. (2008). Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons. Journal of neurochemistry, 106: 45–55
[143] Rammes G,Hasenjager A,Sroka-Saidi K,Deussing JM,Parsons CG (2011). Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of beta-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices. Neuropharmacology, 60: 982–990
[144] Nakagami Y,Oda T (2002). Glutamate exacerbates amyloid beta1-42-induced impairment of long-term potentiation in rat hippocampal slices. Japanese journal of pharmacology, 88: 223–226
[145] Li S,Jin M,Koeglsperger T,Shepardson NE,Shankar GM,Selkoe DJ (2011). Soluble Abeta oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. The Journal of neuroscience, 31: 6627–6638
[146] Wang Q,Walsh DM,Rowan MJ,Selkoe DJ,Anwyl R (2004). Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. The Journal of neuroscience, 24: 3370–3378
[147] Shankar GM,Li S,Mehta TH,Garcia-Munoz A,Shepardson NE,Smith I, et al. (2008). Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nature medicine, 14: 837–842
[148] Fitzjohn SM,Irving AJ,Palmer MJ,Harvey J,Lodge D,Collingridge GL (1996). Activation of group I mGluRs potentiates NMDA responses in rat hippocampal slices. Neuroscience letters, 203: 211–213
[149] Alagarsamy S,Marino MJ,Rouse ST,Gereau Iv RW,Heinemann SF,Conn PJ (1999). Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems. Nature neuroscience, 2: 234–240
[150] Bruno V,Copani A,Knopfel T,Kuhn R,Casabona G,Dell’Albani P, et al. (1995). Activation of metabotropic glutamate receptors coupled to inositol phospholipid hydrolysis amplifies NMDA-induced neuronal degeneration in cultured cortical cells. Neuropharmacology, 34: 1089–1098
[151] Bruno V,Ksiazek I,Battaglia G,Lukic S,Leonhardt T,Sauer D, et al. (2000). Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective. Neuropharmacology, 39: 2223–2230
[152] Karanian DA,Baude AS,Brown QB,Parsons CG,Bahr BA (2006). 3-Nitropropionic acid toxicity in hippocampus: protection through N-methyl-D-aspartate receptor antagonism. Hippocampus, 16: 834–842
[153] Zieminska E,Lazarewicz JW (2006). Excitotoxic neuronal injury in chronic homocysteine neurotoxicity studied in vitro: the role of NMDA and group I metabotropic glutamate receptors. Acta neurobiologiae experimentalis, 66: 301–309
[154] Chen X,Lin R,Chang L,Xu S,Wei X,Zhang J, et al. (2013). Enhancement of long-term depression by soluble amyloid beta protein in rat hippocampus is mediated by metabotropic glutamate receptor and involves activation of p38MAPK, STEP and caspase-3. Neuroscience, 253: 435–443
[155] Hoover BR,Reed MN,Su J,Penrod RD,Kotilinek LA,Grant MK, et al. (2010). Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron, 68: 1067–1081.
[156] Kopeikina KJ,Hyman BT,Spires-Jones TL (2012). Soluble forms of tau are toxic in Alzheimer’s disease. Transl Neurosci, 3: 223–233
[157] Crimins JL,Pooler A,Polydoro M,Luebke JI,Spires-Jones TL (2013). The intersection of amyloid beta and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer’s disease. Ageing research reviews, 12: 757–763
[158] Roberson ED,Scearce-Levie K,Palop JJ,Yan F,Cheng IH,Wu T, et al. (2007). Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer’s disease mouse model. Science (New York, N.Y.), 316: 750–754
[159] Rapoport M,Dawson HN,Binder LI,Vitek MP,Ferreira A (2002). Tau is essential to beta -amyloid-induced neurotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 99: 6364–6369
[160] Roberson ED,Halabisky B,Yoo JW,Yao J,Chin J,Yan F, et al. (2011). Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer’s disease. The Journal of neuroscience, 31: 700–711
[161] Nakazawa T,Komai S,Tezuka T,Hisatsune C,Umemori H,Semba K, et al. (2001). Characterization of Fyn-mediated tyrosine phosphorylation sites on GluR epsilon 2 (NR2B) subunit of the N-methyl-D-aspartate receptor. The Journal of biological chemistry, 276: 693–699
[162] Chin J,Palop JJ,Yu GQ,Kojima N,Masliah E,Mucke L (2004). Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. The Journal of neuroscience, 24: 4692–4697
[163] Chin J,Palop JJ,Puolivali J,Massaro C,Bien-Ly N,Gerstein H, et al. (2005). Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer’s disease. The Journal of neuroscience, 25: 9694–9703
[164] Mondragon-Rodriguez S,Trillaud-Doppia E,Dudilot A,Bourgeois C,Lauzon M,Leclerc N, et al. (2012). Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation. The Journal of biological chemistry, 287: 32040–32053
[165] Beattie EC,Carroll RC,Yu X,Morishita W,Yasuda H,von Zastrow M, et al. (2000). Regulation of AMPA receptor endocytosis by a signaling mechanism shared with LTD. Nature neuroscience, 3: 1291–1300
[166] Hsieh H,Boehm J,Sato C,Iwatsubo T,Tomita T,Sisodia S, et al. (2006). AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron, 52: 831–843
[167] Reifert J,Hartung-Cranston D,Feinstein SC (2011). Amyloid beta-mediated cell death of cultured hippocampal neurons reveals extensive Tau fragmentation without increased full-length tau phosphorylation. The Journal of biological chemistry, 286: 20797–20811
[168] Takashima A,Noguchi K,Sato K,Hoshino T,Imahori K (1993). Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 90: 7789–7793
[169] Zheng WH,Bastianetto S,Mennicken F,Ma W,Kar S (2002). Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. Neuroscience, 115: 201–211
[170] Buckner RL,Sepulcre J,Talukdar T,Krienen FM,Liu H,Hedden T, et al. (2009). Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer’s disease. The Journal of neuroscience : the official journal of the Society for Neuroscience, 29: 1860–1873
[171] Cirrito JR,Yamada KA,Finn MB,Sloviter RS,Bales KR,May PC, et al. (2005). Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron, 48: 913–922
[172] Yamada K,Holth JK,Liao F,Stewart FR,Mahan TE,Jiang H, et al. (2014). Neuronal activity regulates extracellular tau in vivo. The Journal of experimental medicine, 211: 387–393
[173] Wheeler DD,Ondo JG (1986). Time course of the aging of the high affinity L-glutamate transporter in rat cortical synaptosomes. Exp Gerontol., 21: 159–168.
[174] Najlerahim A,Francis PT,Bowen DM (1990). Age-related alteration in excitatory amino acid neurotransmission in rat brain. Neurobiol Aging, 11: 155–158.
[175] Nickell J,Salvatore MF,Pomerleau F,Apparsundaram S,Gerhardt GA (2007). Reduced plasma membrane surface expression of GLAST mediates decreased glutamate regulation in the aged striatum. Neurobiol Aging., 28: 1737–1748. Epub 2006 Sep 1737.
[176] Meur KL,Galante M,Angulo MC,Audinat E (2007). Tonic activation of NMDA receptors by ambient glutamate of non-synaptic origin in the rat hippocampus. The Journal of Physiology, 580: 373–383
[177] Potier B,Billard J-M,Rivière S,Sinet P-M,Denis I,Champeil-Potokar G, et al. (2010). Reduction in glutamate uptake is associated with extrasynaptic NMDA and metabotropic glutamate receptor activation at the hippocampal CA1 synapse of aged rats. Aging Cell, 9: 722–735
[178] Nakanishi S,Masu M (1994). Molecular diversity and functions of glutamate receptors. Annual review of biophysics and biomolecular structure, 23: 319–348
[179] Karim F,Wang CC,Gereau RWt (2001). Metabotropic glutamate receptor subtypes 1 and 5 are activators of extracellular signal-regulated kinase signaling required for inflammatory pain in mice. The Journal of neuroscience, 21: 3771–3779
[180] Ayala JE,Chen Y,Banko JL,Sheffler DJ,Williams R,Telk AN, et al. (2009). mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning. Neuropsychopharmacology, 34: 2057–2071
[181] Neyman S,Manahan-Vaughan D (2008). Metabotropic glutamate receptor 1 (mGluR1) and 5 (mGluR5) regulate late phases of LTP and LTD in the hippocampal CA1 region in vitro. The European journal of neuroscience, 27: 1345–1352
[182] Biber K,Laurie DJ,Berthele A,Sommer B,Tolle TR,Gebicke-Harter PJ, et al. (1999). Expression and signaling of group I metabotropic glutamate receptors in astrocytes and microglia. Journal of neurochemistry, 72: 1671–1680
[183] Kirischuk S,Kirchhoff F,Matyash V,Kettenmann H,Verkhratsky A (1999). Glutamate-triggered calcium signalling in mouse bergmann glial cells in situ: role of inositol-1,4,5-trisphosphate-mediated intracellular calcium release. Neuroscience, 92: 1051–1059
[184] Verkhratsky A,Kirchhoff F (2007). Glutamate-mediated neuronal-glial transmission. Journal of anatomy, 210: 651–660
[185] Bond A,Ragumoorthy N,Monn JA,Hicks CA,Ward MA,Lodge D, et al. (1999). LY379268, a potent and selective Group II metabotropic glutamate receptor agonist, is neuroprotective in gerbil global, but not focal, cerebral ischaemia. Neuroscience letters, 273: 191–194
[186] Poschel B,Manahan-Vaughan D (2005). Group II mGluR-induced long term depression in the dentate gyrus in vivo is NMDA receptor-independent and does not require protein synthesis. Neuropharmacology, 49 Suppl 1: 1–12
[187] Yao HH,Ding JH,Zhou F,Wang F,Hu LF,Sun T, et al. (2005). Enhancement of glutamate uptake mediates the neuroprotection exerted by activating group II or III metabotropic glutamate receptors on astrocytes. Journal of neurochemistry, 92: 948–961
[188] Shigemoto R,Kinoshita A,Wada E,Nomura S,Ohishi H,Takada M, et al. (1997). Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. The Journal of neuroscience, 17: 7503–7522
[189] Pinheiro PS,Mulle C (2008). Presynaptic glutamate receptors: physiological functions and mechanisms of action. Nature reviews. Neuroscience, 9: 423–436
[190] Geurts JJ,Wolswijk G,Bo L,Redeker S,Ramkema M,Troost D, et al. (2005). Expression patterns of Group III metabotropic glutamate receptors mGluR4 and mGluR8 in multiple sclerosis lesions. Journal of neuroimmunology, 158: 182–190
[191] Saugstad JA,Kinzie JM,Shinohara MM,Segerson TP,Westbrook GL (1997). Cloning and expression of rat metabotropic glutamate receptor 8 reveals a distinct pharmacological profile. Molecular pharmacology, 51: 119–125
[1] Jong Bin Bae,Ji Won Han,Kyung Phil Kwak,Bong Jo Kim,Shin Gyeom Kim,Jeong Lan Kim,Tae Hui Kim,Seung-Ho Ryu,Seok Woo Moon,Joon Hyuk Park,Jong Chul Youn,Dong Young Lee,Dong Woo Lee,Seok Bum Lee,Jung Jae Lee,Jin Hyeong Jhoo,Ki Woong Kim. Is Dementia More Fatal Than Previously Estimated? A Population-based Prospective Cohort Study[J]. Aging and disease, 2019, 10(1): 1-11.
[2] Antonina Luca, Carmela Calandra, Maria Luca. Molecular Bases of Alzheimer’s Disease and Neurodegeneration: The Role of Neuroglia[J]. Aging and disease, 2018, 9(6): 1134-1152.
[3] Sone Daichi, Imabayashi Etsuko, Maikusa Norihide, Ogawa Masayo, Sato Noriko, Matsuda Hiroshi, Japanese-Alzheimer’s Disease Neuroimaging Initiative. Voxel-based Specific Regional Analysis System for Alzheimer’s Disease (VSRAD) on 3-tesla Normal Database: Diagnostic Accuracy in Two Independent Cohorts with Early Alzheimer’s Disease[J]. Aging and disease, 2018, 9(4): 755-760.
[4] Morroni Fabiana, Sita Giulia, Graziosi Agnese, Turrini Eleonora, Fimognari Carmela, Tarozzi Andrea, Hrelia Patrizia. Neuroprotective Effect of Caffeic Acid Phenethyl Ester in A Mouse Model of Alzheimer’s Disease Involves Nrf2/HO-1 Pathway[J]. Aging and disease, 2018, 9(4): 605-622.
[5] Xu Yangqi, Liu Xiaoli, Shen Junyi, Tian Wotu, Fang Rong, Li Binyin, Ma Jianfang, Cao Li, Chen Shengdi, Li Guanjun, Tang Huidong. The Whole Exome Sequencing Clarifies the Genotype- Phenotype Correlations in Patients with Early-Onset Dementia[J]. Aging and disease, 2018, 9(4): 696-705.
[6] Ding Qiong, Tanigawa Kitora, Kaneko Jun, Totsuka Mamoru, Katakura Yoshinori, Imabayashi Etsuko, Matsuda Hiroshi, Hisatsune Tatsuhiro. Anserine/Carnosine Supplementation Preserves Blood Flow in the Prefrontal Brain of Elderly People Carrying APOE e4[J]. Aging and disease, 2018, 9(3): 334-345.
[7] Shen Ting, You Yuyi, Joseph Chitra, Mirzaei Mehdi, Klistorner Alexander, Graham Stuart L., Gupta Vivek. BDNF Polymorphism: A Review of Its Diagnostic and Clinical Relevance in Neurodegenerative Disorders[J]. Aging and disease, 2018, 9(3): 523-536.
[8] Peng Fangyu, Xie Fang, Muzik Otto. Alteration of Copper Fluxes in Brain Aging: A Longitudinal Study in Rodent Using 64CuCl2-PET/CT[J]. Aging and disease, 2018, 9(1): 109-118.
[9] Castillo-Carranza Diana L, Nilson Ashley N, Van Skike Candice E, Jahrling Jordan B, Patel Kishan, Garach Prajesh, Gerson Julia E, Sengupta Urmi, Abisambra Jose, Nelson Peter, Troncoso Juan, Ungvari Zoltan, Galvan Veronica, Kayed Rakez. Cerebral Microvascular Accumulation of Tau Oligomers in Alzheimer’s Disease and Related Tauopathies[J]. Aging and disease, 2017, 8(3): 257-266.
[10] Sternberg Zohara, Hu Zihua, Sternberg Daniel, Waseh Shayan, Quinn Joseph F., Wild Katharine, Jeffrey Kaye, Zhao Lin, Garrick Michael. Serum Hepcidin Levels, Iron Dyshomeostasis and Cognitive Loss in Alzheimer’s Disease[J]. Aging and disease, 2017, 8(2): 215-227.
[11] Zaia Annamaria, Maponi Pierluigi, Di Stefano Giuseppina, Casoli Tiziana. Biocomplexity and Fractality in the Search of Biomarkers of Aging and Pathology: Focus on Mitochondrial DNA and Alzheimer’s Disease[J]. Aging and disease, 2017, 8(1): 44-56.
[12] Wang Jianhui, Cheng Xiaorui, Zeng Ju, Yuan Jiangbei, Wang Zhongfu, Zhou Wenxia, Zhang Yongxiang. LW-AFC Effects on N-glycan Profile in Senescence-Accelerated Mouse Prone 8 Strain, a Mouse Model of Alzheimer’s Disease[J]. Aging and disease, 2017, 8(1): 101-114.
[13] Lanznaster Débora, Dal-Cim Tharine, Piermartiri Tetsadê C. B., Tasca Carla I.. Guanosine: a Neuromodulator with Therapeutic Potential in Brain Disorders[J]. Aging and disease, 2016, 7(5): 657-679.
[14] Gurses Murat Serdar, Ural Mustafa Numan, Gulec Mehmet Akif, Akyol Omer, Akyol Sumeyya. Pathophysiological Function of ADAMTS Enzymes on Molecular Mechanism of Alzheimer’s Disease[J]. Aging and disease, 2016, 7(4): 479-490.
[15] Day Ryan J., McCarty Katie L., Ockerse Kayla E., Head Elizabeth, Rohn Troy T.. Proteolytic Cleavage of Apolipoprotein E in the Down Syndrome Brain[J]. Aging and disease, 2016, 7(3): 267-277.
Full text



Copyright © 2014 Aging and Disease, All Rights Reserved.
Address: Aging and Disease Editorial Office 3400 Camp Bowie Boulevard Fort Worth, TX76106 USA
Fax: (817) 735-0408 E-mail:
Powered by Beijing Magtech Co. Ltd